Renovis Completes Enrollment in Postherpetic Neuralgia Trial of REN-1654

Renovis has completed enrollment of patients in its Phase II trial of REN-1654 in the treatment of postherpetic neuralgia (PHN), an often debilitating form of neuropathic pain that can occur in patients following an outbreak of shingles.

The primary goal of this trial was to assess the safety and effectiveness of REN-1654 in treating acute pain in PHN patients. The Phase II trial of REN-1654 in PHN patients was a randomized, double-blind, placebo-controlled trial that enrolled more than 90 patients at multiple centers in the U.S. Patients enrolled in the trial were administered one of two dose levels of REN-1654, or placebo, during a three-week treatment period.

The effectiveness of REN-1654 will be assessed based on the change in pain levels and quality of life scores experienced by patients who received REN-1654 during the treatment period compared to those who received placebo.